Women with sickle cell disease (SCD) have markedly elevated levels of C-reactive protein (CRP), a marker of body-wide inflammation, during the first half of their menstrual cycles, and these variations may contribute to recurrent patterns of vaso-occlusive events (VOEs), complications resulting from blood vessel obstruction that include painful…
Researchers have developed a modelling system of tiny blood vessels to track inflammation-driven blood clot formation that can cause complications in sickle cell disease (SCD) and other conditions. “One of the biggest things about being able to create [blood clots] under inflammatory conditions is that we are now able…
Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of Lyfgenia (lovotibeglogene autotemcel), Bluebird’s gene therapy for sickle cell disease, incorporating Xcellbio technology into Bluebird’s potency assay with the aim of helping to ensure the therapy’s effectiveness. “We’re humbled to play a small part in…
A toolkit may facilitate the active involvement of parents of young children with sickle cell disease (SCD) in shared decision-making regarding hydroxyurea treatment for their children, a study suggests. However, the odds of these young patients being offered and prescribed hydroxyurea were higher among those who received usual…
This year, for the first time, two teenagers in Florence, South Carolina, are going to be able to go swimming on spring break without worrying about serious complications from sickle cell disease (SCD). Ashanti and Dontrell Pickens have long wanted to swim on their school holidays, but were not…
This month, the University of Tennessee Health Science Center College of Nursing is hosting a conference that aims to educate primary care doctors about sickle cell disease (SCD). The Sickle Cell Disease Comprehensive Management for Health Care Providers conference is being funded by a two-year, $364,502 grant from the…
Scientists have discovered more than a dozen genes that regulate the production of fetal hemoglobin in people of African descent, which may be potential treatment targets for sickle cell disease (SCD). Their findings were reported in the study, “FLT1 and other candidate fetal haemoglobin modifying loci…
People with sickle cell disease (SCD) who are hospitalized for opioid overdose have fewer serious complications than those without the condition, but face longer hospital stays, higher costs, and unique healthcare challenges that require specialized care, a study found. “A multidisciplinary approach to pain management, tailored to individual patient…
Zynext Ventures is investing in Illexcor Therapeutics to advance the clinical development of ILX002, its lead, novel oral candidate therapy for sickle cell disease (SCD), the companies announced. The financial details of the investment by Zynext Ventures, the venture capital arm of Zydus Lifesciences, were not disclosed.
Hydroxyurea may effectively reduce the risk of stroke in children with sickle cell disease (SCD), a systematic review has found. “This review highlights the need for further research to understand the real-world feasibility and practical implications of hydroxyurea dosing strategies and to explore its long-term safety and efficacy…
Get regular updates to your inbox.